Emergence of Hepatitis C Virus Genotype Recombinant Forms 2k/1b in Georgia

Zakalashvili, Mamuka; Weizenegger, Michael; Bartel, Jan; Markowski, Monika; Zarkua, Jaba; Kavsadze, Salome; Kvatadze, K.; Basheleishvili, George; Phirtskhalaishvili, Tamar; Dzagania, Tamar; Zangurashvili, Lela; Kankia, Nino; Jashiashvili, Nino; Lomidze, Maka; Telia, Tengiz; Kerashvili, Vakhtang; Zhamutashvili, Maia; Abramishvili, Nikoloz; Rtskhiladze, Irakli; Metreveli, David

doi:10.7754/clin.lab.2016.151210

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Full genome sequencing confirmed the results. The phylogenetic analysis showed that the RF_2k/1b viruses from Georgia formed a monophyletic cluster with the previously described RF1_2k/1b sequences 8,9 …”

Section: Introductionmentioning

confidence: 58%

Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

Zakalashvili¹,

Zarkua²,

Gish

et al. 2020

Hepatology Research

Self Cite

View full text Add to dashboard Cite

Aim Hepatitis C virus (HCV) intergenotype recombinant form (RF) 2k/1b has been actively circulating in HCV‐infected patients, and the prevalence of this RF virus in the Republic of Georgia is one of the highest reported worldwide. The aim of this study was to define the optimal treatment regimen for patients with RF_2k/1b. Methods We analyzed the data of 2735 patients who started treatment at the Medical Center Mrcheveli within Georgia's hepatitis C elimination program from May 2015 through December 2019. The patients were treated with sofosbuvir (SOF)‐based regimens. For identification of RF_2k/1b variants, refinement of standard (INNO‐LiPA) genotyping results for all patient samples assigned the unspecific HCV genotypes (GT) 2a/2c was carried out by sequencing of core and non‐structural protein 5B genes. Results Overall, 444 patients, representing 66% of GT2 and 16% of the total samples, were RF_2k/1b. Treatment of patients with RF_2k/1b with SOF/ledipasvir and SOF/velpatasvir was highly effective and viral cure rates did not differ among genotypes treated with the same regimen: RF_2k/1b, 99% (343/346); GT1, 99% (876/885); GT2, 96% (156/162); and GT3, 99% (545/552). A separate comparison analysis of sustained virologic response rate, treated with SOF plus ribavirin, showed significantly higher sustained virologic response (96%) in patients with confirmed GT2 (by sequencing) compared to unspecified GT2 (by INNO‐LiPA) (79%) (P < 0.05). Conclusion Sofosbuvir‐based regimens are highly effective for treatment of RF 2k/1b patients, and with availability of new pan‐genotypic direct‐acting antivirals, genotyping to identify RF 2k/1b patients might not be necessary.

show abstract

Section: Introductionmentioning

confidence: 58%

Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

Zakalashvili¹,

Zarkua²,

Gish

et al. 2020

Hepatology Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…When “mixed” genotypes are seen, the finding is usually attributed to a “coinfection” with 2 separate variants. In a pilot study in which we evaluated the prevalence of HCV recombinant forms in CHC patients in Georgia, approximately 18.5% were identified as the recombinant form 2k/1b, a prevalence that is far higher than had previously been reported in any other country. To determine the validity of this surprisingly high prevalence, we evaluated the prevalence of this recombinant form in a much larger population of patients and performed phylogenetic analyses to further investigate the genetic relationship with previously described recombinant forms.…”

Section: Introductionmentioning

confidence: 86%

Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia

Zakalashvili¹,

Zarkua²,

Weizenegger

et al. 2017

Liver International

Self Cite

View full text Add to dashboard Cite

show abstract

Comparison of cobas HCV GT against Versant HCV Genotype 2.0 (LiPA) with confirmation by Sanger sequencing

Yusrina

Chua

Lee

et al. 2018

Journal of Virological Methods

View full text Add to dashboard Cite

Emergence of Hepatitis C Virus Genotype Recombinant Forms 2k/1b in Georgia

Abstract: We can conclude that almost 20% of HCV infected Georgian patients are infected with HCVRF_2k/ 1b.

Cited by 3 publications

References 0 publications

Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b

Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia

Comparison of cobas HCV GT against Versant HCV Genotype 2.0 (LiPA) with confirmation by Sanger sequencing

Contact Info

Product

Resources

About